Treatment of Patients With Neovascular AMD Using Indocyanine Green-Mediated Photothrombosis (i-MP).

Exclusion Criteria

• •BCVA lesser than 20/400;
• •Greatest linear dimension of the neovascular complex greater than 6000 (six thousand) micron;
• •Previous Photodynamic Therapy (PDT);
• •Thermal laser for the treatment of any CNV;
• •Intra vitreous injection of corticosteroids or anti-angiogenic drugs;
• •Opacities of the media that can significantly interfere on the VA, clinical ophthalmic assessment, documentation of the eye fundus and performance of laser therapy;
• •Other causes of CNV such as pathologic myopia (spherical equivalent greater than 6 \[six\] spherical diopters and/or axial length greater than 26mm), angioid streaks, active uveitis, ocular presumed histoplasmosis and traumatic choroidal rupture;
• •CNV associated to serous/sero hemorrhagic RPED (vascular RPED / hemorrhagic RPED);
• •Absence of identifiable CNV by fluorescein angiography (massive presence of thick blood);
• •CNV with absence of ICG uptake by ICG angiography despite the eligibility of the patient by clinical criteria and fluorescein angiography;
• •Intraocular surgery undertaken in the last 3 months;
• •Posterior vitrectomy or retinopexy with scleral introflexion, at any time;
• •Severe form of non-proliferative Diabetic Retinopathy;
• •Acute ocular infection;
• •Ionizing radiation treatment on the face, skull and neck region;
• •Allergy to fluorescein or indocyanine green;
• •Excessive known use of alcohol or drugs;
• •Medical or psychological conditions which may impede the patient of completing the study or sing the Informed Consent Form;
• •Significant uncontrolled disease which, in the opinion of the investigator, may exclude the patient from the study;
• •Impediment or limited legal capability;
• •Participation in other clinical study in the last 30 days. NOTE: Patients who have participated of any clinical study in the last 12 months, even though they had finished their participation prior to the last 30 days, will only be eligible to inclusion if the participation in the present protocol will bring clear benefit to the patient.